Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy

Lin, Meng-JuMeng-JuLinTUNG-HUNG SUCHUN-JEN LIUHUNG-CHIH YANGCHI-LING CHENJYH-MING LIOUTAI-CHUNG TSENGCHEN-HUA LIUCHUN-MING HONGPEI-JER CHENJIA-HORNG KAO2023-06-132023-06-132023-070929-6646https://scholars.lib.ntu.edu.tw/handle/123456789/632648Distinct hepatitis relapse has been observed after discontinuing entecavir (ETV) or tenofovir disoproxil fumarate (TDF) therapy in chronic hepatitis B (CHB) patients. End-of-therapy (EOT) serum cytokines were compared and used for outcome prediction.enAntiviral therapy; Chronic hepatitis B; Cytokine; Hepatitis flare; Nucleos(t)ide analogueSerum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapyjournal article10.1016/j.jfma.2023.02.002368721312-s2.0-85149764092https://api.elsevier.com/content/abstract/scopus_id/85149764092